Krensavage Asset Management
Krensavage Asset Management reported 20 stocks worth $265M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are JAZZ (14.6%), ENTA (14.2%) and UTHR (13.5%). Compared with Q2 2026, the fund opened new positions in ANIP, ACAD and ZTS, added to RARE, SUPN and SNY, trimmed UTHR, EXEL and EOLS and sold out of REGN.
Latest filing: what Krensavage Asset Management did in Q3 2026
vs Q2 2026
REGN$3.7M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() JAZZ Jazz Pharmaceuticals PLC | $38.9M | 14.6% | 168K | No change | 8 of 8 | |
| 2 | ![]() ENTA Enanta Pharmaceuticals Inc | $37.8M | 14.2% | 2.9M | No change | 8 of 8 | |
| 3 | ![]() UTHR United Therapeutics Corp Del | $35.9M | 13.5% | 66K | −3,000 (−4%) | 8 of 8 | |
| 4 | ![]() BMRN Biomarin Pharmaceutical Inc | $31.5M | 11.9% | 525K | No change | 5 of 8 | |
| 5 | ![]() ABT Abbott Labs | $19.8M | 7.5% | 200K | No change | 3 of 8 | |
| 6 | ![]() EXEL Exelixis Inc | $17.5M | 6.6% | 299K | −71K (−19%) | 8 of 8 | |
| 7 | ![]() RARE Ultragenyx Pharmaceutical in | $17.1M | 6.5% | 1.1M | +750K (+192%) | 4 of 8 | |
| 8 | ![]() SUPN Supernus Pharmaceuticals Inc | $15.1M | 5.7% | 351K | +70K (+25%) | 7 of 8 | |
| 9 | ![]() SNY Sanofi | $13.8M | 5.2% | 334K | +10K (+3%) | 8 of 8 | |
| 10 | ![]() EMBC Embecta Corp | $6.4M | 2.4% | 1.1M | No change | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() REGN Regeneron Pharmaceutical | $3.7M | 6,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Krensavage Asset Management 13F FAQ
What does Krensavage Asset Management own?
Krensavage Asset Management reported 20 stocks worth $265M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are JAZZ (14.6%), ENTA (14.2%) and UTHR (13.5%). The table above lists every position in the filing (the top 10 without an account).
What did Krensavage Asset Management buy and sell in Q3 2026?
Compared with Q2 2026: 3 new positions, 4 added to, 3 trimmed and 1 sold out. New positions include ANIP, ACAD and ZTS. It sold all of REGN.
When will Krensavage Asset Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Krensavage Asset Management's portfolio worth?
The Q3 2026 filing reports $265M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.














